ライフサイエンスコーパス: anticancer

1 However, the mechanisms underlying the anticancer action of iron chelation are not fully unders

2 Therefore, the potent anticancer activities of NR4A1 antagonists are also acco

3 strategies have been employed to improve the anticancer activities of oncolytic PVs, including develo

4 lus licheniformis KT921419) displayed strong anticancer activity against HT-29 colon cancer cell line

5 I-2 were synthesized and evaluated for their anticancer activity and impact on drug resistance in com

6 bundant cyclotide in this plant, hyen D, had anticancer activity comparable to that of cycloviolacin

7 ric nanoparticles (ARV-NPs) showed promising anticancer activity in both 2D cell culture and 3D multi

8 e (PP), an anthelmintic drug with documented anticancer activity in preclinical models.

9 gly correlate intracellular accumulation and anticancer activity in tether and nontether complexes.

10 ifferent types of tumors, report a promising anticancer activity induced by CB2R agonists due to thei

11 Here we show that vitamin C anticancer activity is limited by the up-regulation of t

12 uated the effect of these differences on the anticancer activity of ginger by performing efficacy-bas

13 We further propose that the anticancer activity of noscapine arises from a bioactive

14 Here, we describe the anticancer activity of novel congeners of the tubulin-po

15 Here, we investigated a potential anticancer activity of the recently developed non-BET fa

16 tile derivatization while maintaining potent anticancer activity, offering exciting opportunity for t

17 the lactone and diene as moieties conferring anticancer activity, thus identifying priorities for the

18 e of compounds with relevant antioxidant and anticancer activity.

19 class of fungal natural products with potent anticancer activity.

20 oxidant activity, antimicrobial activity and anticancer activity.

21 itamin K2 has been shown to exert remarkable anticancer activity.

22 and have uncovered cyclotides with potential anticancer activity.

23 esponding ETP-triazoles without compromising anticancer activity.

24 ular mechanism of a potent platinum-acridine anticancer agent (compound 1), a correlation analysis of

25 However, it also acts as a weak anticancer agent in certain in vivo models through a mec

26 than one bioactive moiety in a multitargeted anticancer agent may result in synergistic activity of i

27 hesis of mycothiazole, a naturally occurring anticancer agent through a sequence that contains a long

28 Its documented success as an anticancer agent, coupled with early concerns over suppl

29 n-1,12-dien-30-oate (CF(3)DODA-Me), a potent anticancer agent, were studied on cancer-lymphatic inter

30 linically employed and experimental targeted anticancer agents also mediate immunostimulatory or immu

31 panion (pet) dogs, allow assessment of novel anticancer agents and combination therapies in a veterin

32 he main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harne

33 suggest a possible use of NK-derived EVs as anticancer agents and propel the development of new stra

34 ith conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecu

35 ed for a set of rigidified platinum-acridine anticancer agents containing linkers derived from chiral

36 future development of additional efficacious anticancer agents derived from natural products.

37 rodent protoparvoviruses (PVs) are promising anticancer agents due to their excellent safety profile,

38 ities of established drugs and other rhenium anticancer agents in the TRIP-resistant cell line were d

39 Anticancer agents often cause drug-induced tetraploidy (

40 w summarizes previous studies on metal-based anticancer agents that cause ER stress.

41 be considered a new class of zinc-chelating anticancer agents that deserves further development.

42 a (TOP2alpha/170) is an important target for anticancer agents whose efficacy is often attenuated by

43 Surface MHC levels can be modulated by anticancer agents, altering immunity.

44 ors (NRTIs) are widely used as antiviral and anticancer agents, although they require intracellular p

45 her therapeutic classes (neurological drugs, anticancer agents, and many others), can prolong the QT

46 er herpesviruses, and (ii) be developed into anticancer agents, as functions of KAP1 and ATM are tigh

47 s predictive of sensitivity or resistance to anticancer agents, but the identification of actionable

48 eeper mechanistic insight into these rhenium anticancer agents, we developed and characterized an ova

49 e clinical utility in the development of new anticancer agents.

50 xes have been recently investigated as novel anticancer agents.

51 gned, synthesized and evaluated as potential anticancer agents.

52 p G-quadruplex binders as safe and effective anticancer agents.

53 C), were originally and are still pursued as anticancer agents.

54 ns, often after chronic exposure to targeted anticancer agents.

55 s recently emerged as a promising target for anticancer agents.

56 t HMGA2 is a potential therapeutic target of anticancer and anti-obesity drugs by inhibiting its DNA-

57 used as a scaffold for developing potential anticancer and antibiotic agents.

58 The simultaneous determination of anticancer and antibiotic drugs in biological samples wi

59 ehydes Tat-A and Tat-B showed low micromolar anticancer and antifungal activities and synergistic act

60 ell-penetrating peptide-based construct with anticancer and antimicrobial activities.

61 The promising anticancer and c-Myc-targeted activities of EMD support

62 uticals, including antiviral, antibacterial, anticancer and cardiac drugs(6,7).

63 e growth of probiotic microflora, MOS impart anticancer and immunomodulatory effects by inducing diff

64 ered best practices for the delivery of oral anticancer and supportive care drugs was performed to Ap

65 tioxidant, antimicrobial, anti-inflammatory, anticancer, antidiabetic, wound healing, anti-HIV, anti-

66 antioxidant, antimicrobial, antityrosinase, anticancer, antihyperlipidemia, antiulcer, anti-inflamma

67 es were proposed for this compound including anticancer, antimicrobial, anti-inflammation, and anti-d

68 nd the compounds discovered, including their anticancer, antimicrobial, antioxidant, and antidiabetic

69 iomimetic nanovaccines for antibacterial and anticancer applications is discussed, with an emphasis o

70 ould be productively exploited for potential anticancer applications.

71 cted significant attention for its potential anticancer applications.

72 Demonstrating system bias as an effective anticancer approach, our study reveals a novel strategy

73 ffective anticancer cargo as a promising new anticancer approach.

74 bination with ETC inhibitors, as a potential anticancer approach.

75 nses characteristic of ICD and to provide an anticancer benefit in vivo.

76 g approach proposed here can identify potent anticancer candidates from the ginger fingerprint withou

77 , we discovered HDR-suppressing functions of anticancer cardiac glycosides in human glioblastomas and

78 tegies to enrich EVs with the most effective anticancer cargo as a promising new anticancer approach.

79 In this Review, we discuss the ability of anticancer cell cycle inhibitors to modulate various imm

80 oprotein that regulates signaling induced by anticancer chemotherapy and growth factors.

81 limit the clinical success of this essential anticancer chemotherapy.

82 cells with a newly developed thienopyridine anticancer compound (3-amino-N-(3-chloro-2-methylphenyl)

83 l PARP/PI3K inhibitor, is a highly effective anticancer compound.

84 scriptomics to identify a common MoA for the anticancer compounds RITA, aminoflavone (AF), and oncras

85 s to predict drug sensitivity for 265 common anticancer compounds.

86 ophytodienoic acid, in synergy, could act as anticancer compounds.

87 of drugs that show enhancements in selective anticancer cytotoxicity against MCF-7 breast cancer cell

88 s from two NRPSs involved in biosynthesis of anticancer depsipeptides thiocoraline and echinomycin, a

89 th peptoid (PE2) can be used as carriers for anticancer drug and protein, where the peptoid modulated

90 Despite recent structural insights, no anticancer drug bound to ABCG2 has been resolved, and th

91 Due to the great potential expressed by an anticancer drug candidate previously reported by our gro

92 n innovative framework for discovering novel anticancer drug candidates.

93 get agents is an emerging approach in modern anticancer drug discovery.

94 ell apoptosis showed that NWs loaded with an anticancer drug displayed long blood-circulation time an

95 rameworks (nCOFs) were first loaded with the anticancer drug Doxorubicin (Dox), coated with magnetic

96 , as compared to an IC(50) = 120 muM for the anticancer drug etoposide] with excellent metabolic stab

97 sensor for the simultaneous determination of anticancer drug Flutamide (FLU) and antibiotic drug Nitr

98 ctive precursor of the potent broad-spectrum anticancer drug paclitaxel (a.k.a. Taxol) that is stable

99 regulatory pathways and programs involved in anticancer drug resistance.

100 ors for antibacterial activity and found the anticancer drug sorafenib as major hit that effectively

101 on extracellularly, thereby enabling in situ anticancer drug synthesis and screening without the cata

102 lls; however, this receptor is an attractive anticancer drug target owing to the overexpression of FR

103 herapeutic agents, including next generation anticancer drug targets with amplified effectivity.

104 the delivery of nucleoside analogues used in anticancer drug therapy.

105 and a hydroxamic acid, which is found in the anticancer drug vorinostat (SAHA).

106 s were used to synthesize catechol (a potent anticancer drug) from salicylic acid to inhibit lung, br

107 Taxol (paclitaxel) is a very widely used anticancer drug, but its commercial sources mainly consi

108 of quickly quantifying concentrations of the anticancer drug, doxorubicin (DOX).

109 Taxol (paclitaxel), a plant-derived anticancer drug, has been among the most successful anti

110 unds that shield ears and kidneys against an anticancer drug.

111 Nearly all anticancer drugs and even novel immunotherapies, which r

112 d OAT1 degrades and unveiled a novel role of anticancer drugs bortezomib and carfilzomib in their reg

113 Anticancer drugs bortezomib and carfilzomib target the u

114 icinal and biological interest, including as anticancer drugs designed to cleave intracellular biomol

115 Anthracycline anticancer drugs doxorubicin and aclarubicin have been u

116 To expand the repertoire of anticancer drugs for injection, acyl and oligo(lactic ac

117 icles, that increase the water solubility of anticancer drugs for injection.

118 I and III) trials supporting FDA approval of anticancer drugs from 1998 to 2018 were evaluated.

119 cytotoxic molecules known, and their use as anticancer drugs has been successfully demonstrated by t

120 high rate of relapse and resistance against anticancer drugs have been associated with a highly abno

121 Many anticancer drugs in clinical use and under investigation

122 posure in murine tumor models, versus parent anticancer drugs in conventional formulations.

123 ed in pivotal trials supporting contemporary anticancer drugs is unknown.

124 cer drug, has been among the most successful anticancer drugs of natural origin.

125 -guided surgery, but also tailor the fate of anticancer drugs such as imatinib (IM) to the tumor site

126 Anticancer drugs targeting TOP2 (TOP2 poisons) prevent r

127 ctic acid) ester prodrugs widen the range of anticancer drugs that can be tested safely and effective

128 Treatment of carcinoma models with anticancer drugs that differ in their mechanism of actio

129 due to reduction of intracellular levels of anticancer drugs through ATP-binding cassette (ABC) pump

130 owever, the overlapping toxicity of multiple anticancer drugs to healthy tissues and increasing finan

131 ystem to optimize the delivery efficiency of anticancer drugs to tumors.

132 re two Food and Drug Administration-approved anticancer drugs, and proteasome is the drug target.

133 To maximize the therapeutic potential of anticancer drugs, combination therapies and multitarget

134 Not limited to anticancer drugs, diagnostic agents can also be achieved

135 e quest for discovery and development of new anticancer drugs, including antibody-drug conjugates as

136 l mechanisms of cancer and in developing new anticancer drugs, it remains extremely challenging to cu

137 The anticancer drugs, mitomycin C (MIC(50) = 0.25 mug/ml) an

138 f various solute carriers to the toxicity of anticancer drugs, the contribution of these proteins to

139 lay superior anticancer efficacy over parent anticancer drugs, which are often approved products.

140 g diagnostics as well as active targeting of anticancer drugs.

141 ndant target for affinity-guided delivery of anticancer drugs.

142 cell death is the therapeutic goal for most anticancer drugs.

143 g promising leads for the development of new anticancer drugs.

144 uld often affect the response of patients to anticancer drugs.

145 isomerase II (topoII), a validated target of anticancer drugs.

146 peutic efficacies and reduce side effects of anticancer drugs.

147 lso enhance body elimination of non-targeted anticancer drugs.

148 novel and potentially safer topoII-targeted anticancer drugs.

149 able molecules such as renewable biofuels or anticancer drugs.

150 esistance in antibiotics, antimicrobials and anticancer drugs.

151 or several US FDA-approved and up-and-coming anticancer drugs.

152 latform to identify both antiherpesviral and anticancer drugs.

153 ght, may find use in the search for improved anticancer drugs.

154 onal design of PAICS inhibitors as potential anticancer drugs.

155 l compound libraries for antiherpesviral and anticancer drugs.IMPORTANCE Epstein-Barr virus, which is

156 e functionalization with peptides for better anticancer effect and current challenges in peptide-func

157 To test the anticancer effect of intermittent fasting from dawn to s

158 insertor administration resulted in enhanced anticancer effects, pointing to a need for more selectiv

159 amycin (mTOR) inhibitors like sirolimus have anticancer effects.

160 igorate cytotoxic T cells, leading to superb anticancer efficacy and robust abscopal effects with >97

161 It showed excellent anticancer efficacy in combination with copper ions (Cu)

162 The in vivo anticancer efficacy is also ascribed to significantly pr

163 Several active clinical trials testing the anticancer efficacy of DSF against various cancers are u

164 determine whether GUS inhibition alters the anticancer efficacy of irinotecan.

165 L nano-assemblies, and they display superior anticancer efficacy over parent anticancer drugs, which

166 diene with a simplified lactone had superior anticancer efficacy relative to taxol, particularly in r

167 Anticancer efficacy studies in WiDr tumor xenograft and

168 he iron-crosslinked Rososomes exhibit better anticancer efficacy than free rosmarinic acid, doxorubic

169 s well as organ damage and provided superior anticancer efficacy, eliciting complete regression of CP

170 complex was also explored to achieve better anticancer efficacy.

171 eptors has been shown to induce inflammatory anticancer events, including differentiation and apoptos

172 iltrating immune cells from performing their anticancer functions.

173 in developing epigenetic therapies to boost anticancer immune responses, either alone or in combinat

174 cell effector functions that are involved in anticancer immunity and also in T cell autoimmune diseas

175 ab to trastuzumab emtansine might potentiate anticancer immunity and enhance the HER2-targeted cytoto

176 s is now known to involve the stimulation of anticancer immunity either by initiating the release of

177 Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through multiple mechanisms and augm

178 pendent kinase 7 (CDK7) inhibitors can evoke anticancer immunity upon genomic destabilization of neop

179 resistance to some bacterial infections, in anticancer immunity, and in anticancer therapies involvi

180 that prevents or attenuates the efficacy of anticancer immunotherapies.

181 Thus, application of anticancer immunotherapy during this critical time frame

182 copper in regulating PD-L1 and suggests that anticancer immunotherapy might be enhanced by pharmacolo

183 In addition, with the renaissance of anticancer immunotherapy, a better understanding of the

184 METTL14 as potential therapeutic targets in anticancer immunotherapy.

185 ssive functions and restores the efficacy of anticancer immunotherapy.

186 complex which was reported as a major active anticancer ingredient for DSF/Cu combination therapy.

187 anges associated with the activity of potent anticancer iron chelators.

188 a membrane during cell migration might be an anticancer mechanism.

189 We also report anticancer molecule RA190, which binds covalently to hRp

190 o yield tumor-specific CD8 T cells, and with anticancer monoclonal antibodies to increase ADCC and an

191 The anthracyclines are structurally diverse anticancer natural products that bind to DNA and poison

192 here are no examples of complex and potently anticancer (nM) ETPs being directly used as conjugatable

193 posing a major pharmacological challenge to anticancer peptide drug development.

194 Despite showing promising anticancer phenotypes, the development of flavagline der

195 structural feature that results in a leap in anticancer potency.

196 Mechanistic understanding of the anticancer potential for STING receptor activation is cu

197 Its anticancer potential has been demonstrated in various st

198 Among various natural products, anticancer potential of phenolics is well established.

199 t that stood out among the others concerning anticancer potential was the one obtained by OH when use

200 cases where an immune response represents an anticancer process.

201 orks, reactive functionalities, and emerging anticancer profiles.

202 In this work, anticancer properties of bis (1,10-phenanthroline) silve

203 nosuppressive phenotype, thus retrieving the anticancer properties of IFNgamma.

204 any which can have antibiotic, antiviral, or anticancer properties that make them interesting for cli

205 Anticancer properties were tested in NMRI mice transplan

206 c polyketide with antibiotic, antifungal and anticancer properties, in S. cerevisiae.

207 prodigiosin, including possible proapoptotic anticancer properties, we investigated how it might affe

208 The median number of previous anticancer regimens was three (IQR 2-4).

209 y for assessing the effects of de-escalating anticancer regimens, which may fast-forward the developm

210 l checkpoint induces T cell infiltration and anticancer responses in murine and human pancreatic canc

211 mour microenvironment in favour of effective anticancer responses.

212 Anticancer strategies utilizing anti-netrin-1 antibody t

213 lications of pulsed magnetic fields in novel anticancer strategies.

214 lation, and suggests activating TiPARP as an anticancer strategy.

215 eting its related regulatory signaling as an anticancer strategy.

216 Targeting polyamine metabolism is a proven anticancer strategy.

217 ing the Hsp70 co-chaperone DNAJA1 as a novel anticancer strategy.

218 tructures is currently viewed as a promising anticancer strategy.

219 activity of cytotoxic T cells is a promising anticancer strategy; but its success is tumor type depen

220 rapy application as demonstrated by in vitro anticancer studies.

221 ession in preclinical models and can improve anticancer T cell responses in patients with advanced ca

222 r vaccines in an optimal format for inducing anticancer T cells.

223 hibitor of PD-L1, which can lead to enhanced anticancer T-cell activity.

224 and adjuvants in nanoparticles for inducing anticancer T-cell immunity.

225 e) has recently emerged as a promising novel anticancer target based on extensive in vitro and in viv

226 inity and high-selectivity compounds for the anticancer target CA IX and antiobesity target CA VB.

227 poly(ADP-ribose) polymerase 1, an important anticancer target in living cells.

228 ceptor alpha (FRalpha) came into focus as an anticancer target many decades after the successful deve

229 cancers and is considered a highly validated anticancer target.

230 enes, and these pathways are novel potential anticancer targets for therapeutic intervention.

231 he most prevalent oncogenes and sought-after anticancer targets, has eluded chemists for decades unti

232 and proteasome) connected to many validated anticancer targets.

233 f V-ATPases as a novel and powerful class of anticancer targets.

234 of this BRD inhibitor to be developed as an anticancer therapeutic agent.

235 fucosylated IgG variants are already used in anticancer therapeutic antibodies for their increased ac

236 kinases (GRK), we explored GRKs as potential anticancer therapeutic targets to disconnect IGF1R downr

237 e important, because metabolic adaptation to anticancer therapeutics is rooted in this inherent metab

238 l discuss the potential of PROTACs to become anticancer therapeutics, chemical and bioinformatics app

239 nt a promising target in the design of novel anticancer therapeutics.

240 targeting PRC2 function for potential use as anticancer therapeutics.

241 d with stress tolerance and poor response to anticancer therapeutics.

242 at interest in applying inhibitors of HIF as anticancer therapeutics.

243 ctivate STAT3 are being pursued as potential anticancer therapies and have led to the identification

244 s low, making combination therapy with other anticancer therapies feasible.

245 seases or use of B cell/plasma cell-directed anticancer therapies have illuminated the biologic relev

246 l infections, in anticancer immunity, and in anticancer therapies involving DNA damage agents.

247 , using FRalpha to better localize effective anticancer therapies to their target tumours using platf

248 Response and resistance to anticancer therapies vary due to intertumor and intratum

249 apsed HCC may aid in the design of effective anticancer therapies, including immunotherapies.

250 er cell killing and form the basis for novel anticancer therapies.

251 potential disease biomarkers and targets of anticancer therapies.

252 ted with poor prognosis and poor response to anticancer therapies.

253 vide a foundation for the development of new anticancer therapies.

254 nvironment of tumors should lead to improved anticancer therapies.

255 improved therapeutic index over conventional anticancer therapies.

256 urther development in combination with other anticancer therapies.

257 as the potential to increase the efficacy of anticancer therapies.

258 in their current indication as antiviral and anticancer therapies.

259 atification of patients with lung cancer for anticancer therapies.

260 lso associated with differential response to anticancer therapies.

261 aphy have limitations in evaluating systemic anticancer therapy (SACT) response in bone metastases fr

262 prognosis resulting from tumor resistance to anticancer therapy and a high recurrence rate.

263 ur data indicate that continuation of active anticancer therapy and follow-up visits in a large terti

264 oles in cancer, Bcl-xL is a major target for anticancer therapy and for studies aimed at understandin

265 m and how their inhibition can contribute to anticancer therapy are discussed.

266 Modalities for photo-triggered anticancer therapy are usually limited by their low pene

267 diagnosis of active cancer alone and recent anticancer therapy do not predict worse COVID-19 outcome

268 Clinically efficacious medication in anticancer therapy has been successfully designed with l

269 All patients anticipating systemic anticancer therapy should be tested for HBV by 3 tests-h

270 antibody to hepatitis B surface antigen-but anticancer therapy should not be delayed.

271 eath comparing patients with recent systemic anticancer therapy to no treatment was 1.17 (95% CI, 0.8

272 nicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associat

273 ique capabilities to resist diverse forms of anticancer therapy, seed recurrent tumours, and dissemin

274 long been considered a rational approach to anticancer therapy, which led to the development of farn

275 r progression, and is a potential target for anticancer therapy.

276 ss and play a crucial role in the outcome of anticancer therapy.

277 traversing delivery vehicle to carry PMI for anticancer therapy.

278 A topoisomerase II is an important target in anticancer therapy.

279 lecule drug design for misfolded proteins in anticancer therapy.

280 ay of adenocarcinoma escape from suppressive anticancer therapy.

281 d limited attention as a potential target of anticancer therapy.

282 suggesting a potential therapeutic index for anticancer therapy.

283 potential to greatly improve the outcomes of anticancer therapy.

284 increasingly common limitation to effective anticancer therapy.

285 COTI-2 is a novel anticancer thiosemicarbazone in phase I clinical trial.

286 patients on cytotoxic chemotherapy or other anticancer treatment are at an increased risk of mortali

287 6.6%) of the patients were undergoing active anticancer treatment in a neoadjuvant/adjuvant and 560 o

288 t of COVID-19 on the prescribing of systemic anticancer treatment in England, immediately after lockd

289 Despite many anticancer treatment regimens consisting of a cocktail o

290 ed therapy resistance is a major problem for anticancer treatment, yet the underlying molecular mecha

291 ries suggest novel RNA-based therapeutics in anticancer treatment.

292 register intention to start all new systemic anticancer treatments approved for use in England since

293 e for many years through the use of systemic anticancer treatments on a background of multidisciplina

294 tic strategies which, combined with existing anticancer treatments, could lead to deeper and longer-l

295 articularly those who are receiving systemic anticancer treatments, have been postulated to be at inc

296 immunity and to hinder the effectiveness of anticancer treatments.

297 e implications for regenerative medicine and anticancer treatments.

298 nisms of oncogenesis and for individualizing anticancer treatments.

299 roenvironment including exposure to targeted anticancer treatments.

300 ponse to different immunotherapy modalities [anticancer vaccination, TC1 (HPV E7 DNA vaccine), alphaP